- Company to appoint Prof. Arun J.
Sanyal as the new Chairman of HistoIndex's Scientific
Advisory Board, bringing unparalleled expertise to guide future
innovations.
- Prof. Vlad Ratziu joins the Scientific Advisory Board to
strengthen the Company's global scientific leadership in liver
disease management.
- HistoIndex's AI-driven solutions qFibrosis, qSteatosis, and
qBallooning can standardize assessments in MASH clinical trials,
improving drug efficacy evaluations and patient screening
processes.
SINGAPORE, July 1, 2024 /PRNewswire/ -- HistoIndex, a global
leader in digital pathology solutions for the management of chronic
liver disease, is pleased to announce changes to its Scientific
Advisory Board (SAB). Established in 2017 under the leadership of
the late Dr. Stephen A. Harrison,
the SAB has played a crucial role in guiding HistoIndex's research
and development efforts. Current members include Prof. Arun J. Sanyal, Prof. Quentin Anstee, Prof. Wei Lai, and Prof. Jacob
George.
New SAB Appointments
Prof. Arun J. Sanyal, a professor
of Medicine, Physiology, and Molecular Pathology at Virginia Commonwealth University (VCU) School of
Medicine, has been appointed as the new Chairman of HistoIndex's
SAB. Also serving as the Director of the Stravitz-Sanyal Institute
for Liver Disease and Metabolic Health at VCU, Prof. Sanyal's
leadership spans multiple prestigious roles as Chair of the NIH
NASH Clinical Research Network, the NIMBLE consortium, and the
Liver Forum. A continuous NIH grant recipient since 1995, Prof.
Sanyal brings well over 500 publications in leading journals to the
role, placing him in the top 0.1% of biomedical scientists
globally. "I am honored to lead HistoIndex's Scientific Advisory
Board," said Prof. Sanyal. "Our collective expertise will
drive innovative solutions in chronic liver disease management,
pushing the boundaries of scientific discovery to improve patient
outcomes."
Prof. Vlad Ratziu, a professor of Hepatology at Sorbonne
University and the Pitié-Salpêtrière Hospital in Paris, also joined the SAB. With over 400
publications and an H-index of 96, Prof. Ratziu is a prominent
researcher in steatotic liver disease and hepatocellular carcinoma.
He has played key roles in numerous MASH therapeutic trials and
European research consortia, and is the incoming Editor-in-Chief of
the Journal of Hepatology, a leading liver disease publication and
the European Association for the Study of the Liver (EASL) flagship
journal. "HistoIndex's technology has ushered in a new era in
quantifying liver injury. The Company's commitment to innovation
and collaboration among industry and academic leaders aligns
perfectly with my scientific pursuits. I am thrilled to join the
scientific board under Prof. Sanyal's leadership and contribute to
innovative work benefiting MASH patients."
Remembering Dr. Stephen A.
Harrison
As we embrace these new changes, we also pause to honor and
remember the exceptional contributions of our late chairman, Dr.
Stephen A. Harrison, a visionary
leader in metabolic disease. His foresight to leverage AI for
disease assessment in 2014 propelled HistoIndex's digital pathology
solutions to the forefront of liver disease management. Dr.
Gideon Ho, CEO of HistoIndex,
reflected, "Stephen was more than our chairman; he was a true
pioneer and mentor whose persistence and guidance brought our
technology to maturation for enhanced patient care. His legacy will
continue to inspire our work as we expand the applications of our
platform technology to other diseases."
Innovative AI Tools
HistoIndex's pioneering AI-based image quantitative tools,
qFibrosis and qSteatosis, have been incorporated in over 25 MASH
clinical trials and demonstrated greater sensitivity in drug
efficacy evaluations and patient stratification. Building on the
same AI foundations, the Company developed qBallooning, which
improved concordance among expert pathologists in ballooned
hepatocyte evaluations. "Developing qBallooning is a significant
step in standardizing and improving the evaluation of liver
biopsies in MASH clinical research and practice," said Dr.
Dean Tai, Chief Scientific Officer.
"With these advancements and our strengthened SAB, HistoIndex is
poised to accelerate liver disease drug development and
diagnosis breakthroughs."
About HistoIndex
Founded in 2010, HistoIndex is a pioneer in stain-free,
fully automated imaging solutions for visualizing and quantifying
fibrosis in tissue biopsies. By combining cutting-edge biophotonic
technology with AI-based analysis, HistoIndex provides innovative
tools that transform research, expedite pharmaceutical drug
development, and set new medical standards.
Photo -
https://mma.prnewswire.com/media/2450751/SAB_Press_release.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/histoindex-charts-new-course-in-liver-disease-innovation-announces-pivotal-changes-to-scientific-advisory-board-302185815.html